However, few data are available for evaluating immunotherapy with FDG PET, especially in lung cancer, for which anti-PD-1 or anti-PDL-1-based immunotherapies are taking a crucial role in treating locally advanced or metastatic tumors [15]. Here, CD274 is linked to lung carcinoma.